Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Thomas R. Cox

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9294-1745; OpenAlex author ID A5033014692. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 13

  1. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  2. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  3. miRNAs in pancreatic cancer progression and metastasis. Last author DOI 10.1007/s10585-023-10256-0↗
  4. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  5. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  6. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  7. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  8. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  9. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Co-author DOI 10.1016/j.trecan.2019.09.010↗
  10. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2017.11.280↗
  11. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  12. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  13. Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy. First author DOI 10.18632/oncotarget.21468↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul Timpson · 6 shared papers, 2017–2021 · strength 0.51
  2. Jessica L. Chitty · 2 shared papers, 2021–2024 · strength 0.44
  3. Claire Vennin · 5 shared papers, 2017–2021 · strength 0.43
  4. Jennifer P. Morton · 5 shared papers, 2018–2021 · strength 0.41
  5. Marina Pajic · 5 shared papers, 2017–2021 · strength 0.41
  6. Ellie T. Y. Mok · 1 shared paper, 2024 · strength 0.36
  7. Brooke Pereira · 3 shared papers, 2019–2021 · strength 0.26
  8. Kendelle Joan Murphy · 3 shared papers, 2018–2021 · strength 0.23
  9. Angela S. Y. Chou · 3 shared papers, 2018–2021 · strength 0.22
  10. Amber L. Johns · 3 shared papers, 2018–2021 · strength 0.22
  11. Anthony James Gill · 3 shared papers, 2018–2021 · strength 0.22
  12. Owen James Sansom · 3 shared papers, 2018–2021 · strength 0.22
  13. Cecilia R. Chambers · 2 shared papers, 2019–2021 · strength 0.18
  14. David Herrmann · 2 shared papers, 2019–2021 · strength 0.18
  15. Ashleigh Parkin · 2 shared papers, 2018–2021 · strength 0.13
  16. Jaswinder Singh Samra · 2 shared papers, 2018–2021 · strength 0.13
  17. Sean Michael Grimmond · 2 shared papers, 2018–2021 · strength 0.13
  18. Andrew Victor Biankin · 2 shared papers, 2018–2021 · strength 0.13
  19. David Goldstein · 1 shared paper, 2021 · strength 0.08
  20. Val Gebski · 1 shared paper, 2021 · strength 0.08
  21. Joshua A. McCarroll · 1 shared paper, 2021 · strength 0.08
  22. Nigel A. Turner · 1 shared paper, 2021 · strength 0.08
  23. Mert Erkan · 1 shared paper, 2021 · strength 0.08
  24. Koroush Shahsavar Haghighi · 1 shared paper, 2021 · strength 0.08
  25. Phoebe A. Phillips · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.